Title : The effect of magnesium sulfate on maternal serum electrolytes in preeclampsia
Abstract:
Magnesium sulfate is the drug of choice in the management of preeclampsia / or eclampsia during pregnancy. Magnesium sulfate (MgSO4) is the drug of choice in the management of preeclampsia / or eclampsia that prevents convulsion and dispenses fetus neuroprotection in preterm labor. Since over-dosage of magnesium sulfate could lead to respiratory and cardiac failure, precise monitoring regarding drug toxicity is performed by periodic assessment of the deep tendon reflexes, urinary output, and respiratory rate.
A total of 30 pregnant women with preeclampsia were evaluated. The patients were administered 4 grams of intravenous MgSO4 followed by a 2 g/hour infusion up to 24 hours after delivery. Sequential blood samples were drawn from each patient and used to measure the serum levels of sodium, potassium, calcium, phosphorus, magnesium, and parathyroid hormone.
The patients were aged between 20 to 41 years with an average gestational age of 36 weeks and 3 days. Only 5 patients reached the therapeutic range of magnesium in at least one of our measuring intervals. Magnesium levels increased significantly during magnesium sulfate administration and dropped remarkably over the next 12 and 24 hours after the infusion cessation (p<0.05). Fifty percent of patients (15 of 30) developed asymptomatic hypocalcemia mainly at the 24 hours of infusion onset. Eleven patients (of 30, 36.6%) developed hyperphosphatemia mainly after 2 and 12 hours of magnesium sulfate infusion.
Our study implies that magnesium sulfate could cause hypermagnesemia-induced hypocalcemia in preeclampsia patients, independent from PTH. A higher risk of severe symptomatic hypocalcemia is anticipated in therapeutic levels of magnesium.
What will audience learn from your presentation?
Magnesium sulfate might induce hypermagnesemia-induced hypocalcemia, independent from PTH, in preeclampsia patients. Patients with therapeutic levels of magnesium are at higher risk of developing severe symptomatic hypocalcemia
